Another TLR7/8 agonist, MEDI9197, was shown to activate pDCs and macrophages leading to interferon-α (IFN-α), IL-12 and IFN-γ release and subsequent antitumor T cell response and tumor regression in syngeneic murine models [102]. Here, IFNG is linked to neoplasm.